Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.535 USD | -5.63% | -18.68% | -26.30% |
May. 20 | HC Wainwright Starts Coverage on Prime Medicine With Buy Rating, $10 Price Target | MT |
May. 17 | North American Morning Briefing : The "Everything -2- | DJ |
Financials (USD)
Sales 2024 * | 4.44M | Sales 2025 * | 3.65M | Capitalization | 801M |
---|---|---|---|---|---|
Net income 2024 * | -193M | Net income 2025 * | -215M | EV / Sales 2024 * | 163 x |
Net cash position 2024 * | 76.98M | Net cash position 2025 * | 205M | EV / Sales 2025 * | 163 x |
P/E ratio 2024 * |
-4.13
x | P/E ratio 2025 * |
-4.59
x | Employees | 234 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 73.52% |
Latest transcript on Prime Medicine, Inc.
1 day | -0.22% | ||
1 week | -8.03% | ||
Current month | +40.75% | ||
1 month | +56.50% | ||
3 months | -26.25% | ||
6 months | -1.49% | ||
Current year | -21.84% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 70 | 20-06-30 | |
Allan Reine
DFI | Director of Finance/CFO | 49 | Jan. 16 |
Chief Operating Officer | 52 | 22-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 64 | 21-11-30 | |
Robert Nelsen
BRD | Director/Board Member | 60 | 20-08-31 |
Michael Kelly
BRD | Director/Board Member | 67 | 21-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.71% | 2 M€ | -25.75% | ||
0.00% | 9 M€ | +10.11% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 6.54 | -5.56% | 920 178 |
24-05-24 | 6.925 | -0.22% | 543,204 |
24-05-23 | 6.94 | -6.85% | 1,250,371 |
24-05-22 | 7.45 | -7.22% | 1,328,759 |
24-05-21 | 8.03 | +6.64% | 1,821,158 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.84% | 801M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.34% | 22.1B | |
-8.28% | 18.34B | |
-41.70% | 16.59B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- PRME Stock